Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.
Our AI
Privacy
15 minute meeting
To explore personalized outperforming therapies.


RARE DISEASE
47,XYY syndrome
47,XYY syndrome
47,XYY syndrome
Synonyms: Double Y syndrome, Jacobs syndrome, XYY syndrome, Y disomy
Synonyms: Double Y syndrome, Jacobs syndrome, XYY syndrome, Y disomy
Synonyms: Double Y syndrome, Jacobs syndrome, XYY syndrome, Y disomy
Drug discovery
32
papers
On emerging therapies
Rare developmental defect during embryogenesis
47,XYY syndrome
Overview
47,XYY Syndrome Overview
47,XYY syndrome is a chromosomal disorder caused by an extra Y chromosome in males, occurring in ∼1/1,000 births. Clinical features include tall stature, hypotonia, motor/speech delays, and increased risks for neurodevelopmental disorders (ADHD, autism spectrum disorder) and comorbidities like asthma and seizures. Most individuals have normal fertility and lifespan, though registry studies suggest a potential 10-year mortality gap linked to neurological/pulmonary diseases. Management focuses on therapies (speech, physical, educational) and treating comorbidities [1][2][5][12].
Burden
Mortality: Increased risk (HR 1.42) for cancer, neurological, and pulmonary diseases [2][16].
Comorbidities: Asthma (39% vs. 9.6% general population), seizures (43%), and tremor [12][16].
Psychosocial impact: Higher rates of unemployment, lower educational attainment, and criminal convictions (linked to socioeconomic factors) [6][12].
Therapies
Early intervention: Physical therapy (hypotonia), speech therapy (delayed language), educational support (learning disabilities) [3][9].
Comorbidity management: Stimulants (ADHD), SSRIs (anxiety/depression), and antiepileptics (seizures) [11][12].
Multidisciplinary care: Genetics, neurology, and psychiatry collaboration for developmental/behavioral challenges [5][9].
Categories: rare developmental anomalies during embryogenesis, rare genetic diseases
Research Papers
32 drug discovery papers about 47,XYY syndrome. Recent publications:
32 drug discovery papers about 47,XYY syndrome. Recent publications:
categories:
Small molecules
small molecules
2026-04-28 | Huperzine A from Chinese Club Moss for Cognitive Enhancement via AChE Inhibition
Huperzine A, isolated from Huperzia serrata, provides highly selective acetylcholinesterase inhibition with superior CNS penetration and longer duration of action compared to conventional inhibitors. It enhances cholinergic signaling in prefrontal and hippocampal circuits while promoting neurogenesis through BDNF upregulation, addressing the learning difficulties and memory deficits in 47,XYY syndrome.
2026-04-28 | Modafinil Repurposing for Executive Function via Dopamine Transporter Modulation
Modafinil's weak dopamine transporter inhibition combined with histaminergic and orexinergic activation provides cognitive enhancement without typical stimulant side effects. Its unique mechanism addresses the executive dysfunction in 47,XYY syndrome by enhancing prefrontal dopaminergic tone while maintaining normal circadian rhythms and avoiding growth suppression concerns of traditional stimulants.
2026-04-28 | Gastrodin from Tianma (TCM) for Executive Function Enhancement via GABA-A Modulation
Gastrodin, the primary bioactive compound from Gastrodia elata, crosses the blood-brain barrier and acts as a positive allosteric modulator of GABA-A receptors while enhancing BDNF expression through CREB phosphorylation. This dual mechanism addresses the executive dysfunction and behavioral issues in 47,XYY syndrome by normalizing GABAergic inhibition and promoting neuroplasticity in prefrontal cortical circuits.
2026-04-28 | Withanoside IV from Ashwagandha for Social Cognition Enhancement via 5-HT2A Modulation
Withanoside IV, a specific withanolide from Withania somnifera, acts as a partial agonist at 5-HT2A receptors while modulating cortical glutamate release through presynaptic mechanisms. This compound addresses the social cognitive deficits in 47,XYY syndrome by enhancing prefrontal-limbic connectivity and normalizing the excitatory-inhibitory balance critical for social information processing.
2025-04-29 | An Overview of Oxidative Stress in Sex Chromosome Aneuploidies in Pediatric Populations
Background: Oxidative stress, defined as an imbalance between reactive oxygen species and antioxidant defenses, plays a pivotal role in the pathogenesis of sex chromosome aneuploidies (SCAs), such as Turner syndrome (TS) and Klinefelter syndrome (KS). Pediatric patients with SCAs are particularly susceptible due to hormonal deficiencies, metabolic disturbances, and systemic complications. Methods: A comprehensive literature search was conducted in November 2024 using PubMed, Scopus, and Web of Science. Keywords included “antioxidants”, “oxidative stress”, “pediatrics”, “Turner syndrome”, “Klinefelter syndrome”, and “sex chromosome aneuploidies”. English-language articles were included without publication year restrictions. Relevant data on oxidative stress mechanisms and antioxidant interventions were systematically extracted. Results: The relationship between oxidative stress and SCAs can be described as bidirectional, where oxidative stress both contributes to and is exacerbated by aneuploidies. TS is marked by estrogen deficiency, cardiovascular anomalies, and metabolic dysfunction, all linked to heightened oxidative stress. KS is associated with hypogonadism, metabolic syndrome, and neurocognitive challenges, further exacerbated by oxidative damage. The aneuploid condition predisposes to increased oxidative stress in other SCAs, including 47,XXX and 47,XYY, as well as in high-grade aneuploidies. Emerging evidence highlights the therapeutic potential of antioxidants, including vitamin C, vitamin E, glutathione precursors, polyphenols, and melatonin. These interventions, when combined with hormonal therapies such as estrogen replacement in TS or testosterone replacement in KS, demonstrate synergistic effects in restoring redox balance and mitigating systemic complications. Conclusions: Oxidative stress significantly impacts the progression of SCAs in pediatric populations, amplifying risks across metabolic, cardiovascular, and neurocognitive domains. Early, tailored antioxidant strategies, integrated with syndrome-specific hormonal therapies, could reduce long-term complications and improve patient outcomes. Future research should focus on standardizing protocols to optimize these interventions for pediatric patients with SCAs.
cell therapies
2022-02-02 | A patient with 47, XYY mosaic karyotype and congenital absence of bilateral vas deferens: a case report and literature review
Abstract Background The incidence of 47, XYY syndrome in live-born male infants is 1/1000. Due to its variable clinical symptoms, the diagnosis is easy to miss. The incidence of congenital bilateral absence of the vas deferens (CBAVD) in infertile men is 1–2%. The main cause is the mutation of CFTR and ADGAG2 genes. Case presentation The patient was a 33-year-old man who visited a doctor 5 years ago due to infertility. The investigation revealed that the patient’s secondary sexual characteristics, testicular, and penis development were normal, and there was no gynecomastia, but the bilateral vas deferens and epididymis were not palpable. Transrectal ultrasound showed that the left seminal vesicle was missing, and the right seminal vesicle was atrophied. No abnormality was observed in Y chromosome microdeletion. Karyotype analysis indicated that the patient was 46, XY/47, XYY mosaic. Genetic testing found heterozygous mutations at two sites of CFTR (c263T > G and c2249C > T). Conclusions Herein, we report the rare case of a male patient with clinical manifestations of infertility, chromosome 46, XY/47, XXY mosaic type, simultaneously manifested as the absence of bilateral vas deferens. Two pathogenic heterozygous CFTR gene mutations were found. Given the low genetic risk of the disease, we recommend that patients undergo intracytoplasmic sperm injection (ICSI) for fertility assessment.
2020-03-16 | Reproductive outcomes of 3 infertile males with XYY syndrome: Retrospective case series and literature review.
The aim of this study is to evaluate the pregnancy outcomes of males with a 47, XYY karyotype following assisted reproductive treatment.A retrospective study was performed using data from infertile men with 47, XYY at a center for reproductive medicine in 2004 to 2017. Of the 19,842 infertile males treated, a total of 21 showed the 47, XYY karyotype and were included in the present study. Clinical variables were collected. Three men were under treatment with their partner before either in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).The incidence of 47, XYY in infertile men is 1/945 (21/19842). Most men are azoospermic or severely oligospermic. Three men and their partners underwent IVF or ICSI treatment with fresh ejaculate samples. The fertilization rate was 52.94% to 83.33%. The embryo cleavage rate was 50% to 90%. One man had abnormal sex hormonal levels and his partner had no clinical pregnancy. The other 2 couples had healthy baby boys.Live spermatozoa can be gathered and fertility is possible for infertile males with 47, XYY syndrome when IVF or ICSI treatment is used. It is recommended that genetic counseling is provided in such cases.
2018-02-27 | Fertile offspring from sterile sex chromosome trisomic mice.
Having the correct number of chromosomes is vital for normal development and health. Sex chromosome trisomy affects 0.1% of the human population and is associated with infertility. We show that during reprogramming to induced pluripotent stem cells (iPSCs), fibroblasts from sterile trisomic XXY and XYY mice lose the extra sex chromosome through a phenomenon we term trisomy-biased chromosome loss (TCL). Resulting euploid XY iPSCs can be differentiated into the male germ cell lineage and functional sperm that can be used in intracytoplasmic sperm injection to produce chromosomally normal, fertile offspring. Sex chromosome loss is comparatively infrequent during mouse XX and XY iPSC generation. TCL also applies to other chromosomes, generating euploid iPSCs from cells of a Down syndrome mouse model. It can also create euploid iPSCs from human trisomic patient fibroblasts. The findings have relevance to overcoming infertility and other trisomic phenotypes.
2011-06-15 | Nonmosaic 47,XYY syndrome presenting with male infertility: case series
In this study, we describe nine patients with 47,XYY presenting with male infertility. All patients were subjected to history taking, clinical examination, duplex ultrasonographic examination of the scrotum, endocrinological investigations and cytogenetic analysis of peripheral lymphocytes. Two patients tried intracytoplasmic sperm injection (ICSI). Our results showed that seven patients were oligospermic and two patients were azoospermic. Bilateral varicocele was detected in seven patients. The hormonal levels in the majority of the patients were within normal range. Two patients showed improvement after varicocelectomy. The wife of one of the oligospermic patients became successfully pregnant after the first trial of ICSI. In conclusion, this report suggests that patients with XYY may present with primary infertility and may show oligospermia and nonobstructive azoospermia. Careful clinical, ultrasonographic, endocrinological and cytogenetic examinations should be a part of their diagnostic work-up for the proper management of these patients. In addition, ICSI may be a hope for some of these patients.
2005-12-01 | Intracytoplasmic sperm injection: a novel selection method for sperm with normal frequency of chromosomal aneuploidies
ObjectiveTo test a newly invented intracytoplasmic sperm injection (ICSI) sperm selection method based on sperm hyaluronic acid (HA) binding.DesignComparison of chromosomal disomy and diploidy frequencies in sperm arising from semen and in HA-bound sperm.SettingAcademic andrology laboratory.Patient(s)Men presenting for semen analysis.Intervention(s)Washed sperm fractions of 32 semen samples were applied to Petri dishes or glass slides coated with immobilized HA. The unbound sperm were rinsed gently, and the HA-bound sperm were removed with an ICSI pipette. The control sperm population was the unselected sperm. Both HA-selected and unselected sperm were treated with fluorescence in situ hybridization with centromeric probes for the X, Y, and 17 chromosomes.Main Outcome Measure(s)Chromosomal disomy and diploidy frequencies.Result(s)In the HA-bound sperm (495–2,079 per man, 41,670 in all) compared with unselected sperm (4,770 per man, 162,210 in all), the chromosomal disomy frequencies were reduced to 0.16% from 0.52%, diploidy to 0.09% from 0.51%, and sex chromosome disomy to 0.05% from 0.27% (a 5.4-fold reduction vs. 4-fold respective increase in ICSI offspring).Conclusion(s)The HA sperm selection method for ICSI, which is based on a relationship between sperm receptors for zona pellucida and HA, will likely reduce the potential genetic complications and adverse public health effects of ICSI. To test a newly invented intracytoplasmic sperm injection (ICSI) sperm selection method based on sperm hyaluronic acid (HA) binding. Comparison of chromosomal disomy and diploidy frequencies in sperm arising from semen and in HA-bound sperm. Academic andrology laboratory. Men presenting for semen analysis. Washed sperm fractions of 32 semen samples were applied to Petri dishes or glass slides coated with immobilized HA. The unbound sperm were rinsed gently, and the HA-bound sperm were removed with an ICSI pipette. The control sperm population was the unselected sperm. Both HA-selected and unselected sperm were treated with fluorescence in situ hybridization with centromeric probes for the X, Y, and 17 chromosomes. Chromosomal disomy and diploidy frequencies. In the HA-bound sperm (495–2,079 per man, 41,670 in all) compared with unselected sperm (4,770 per man, 162,210 in all), the chromosomal disomy frequencies were reduced to 0.16% from 0.52%, diploidy to 0.09% from 0.51%, and sex chromosome disomy to 0.05% from 0.27% (a 5.4-fold reduction vs. 4-fold respective increase in ICSI offspring). The HA sperm selection method for ICSI, which is based on a relationship between sperm receptors for zona pellucida and HA, will likely reduce the potential genetic complications and adverse public health effects of ICSI.
gene therapies
2026-07-07 | CRITICAL STUDY OF THE CONCEPT OF SEX CHROMOSOMES AND CHROMOSOMAL DISORDERS WITH SPECIAL REFERENCE TO STREE VYAPAD AND PURUSH VYAPAD MENTIONED IN AYURVEDA
Background: The ancient Ayurvedic texts contain sophisticated concepts regarding sex determination, hereditary disorders, and reproductive anomalies that demonstrate striking parallels with modern chromosomal science. Classical acharyas such as Charaka and Sushruta described concepts like Beeja (the biological seed — equivalent to the gamete), Beejabhaga (segments or portions of the seed analogous to chromosomes), and Beejabhagavayava (sub-segments of the chromosomal unit analogous to individual genes or sex-determining gene segments), which conceptually correlate with the modern understanding of genes, chromosomes, and sex-determining chromosomal segments. Objectives: This review critically examines the Ayurvedic concepts of Stree Vyapad (abnormal female phenotype) and Purush Vyapad (abnormal male phenotype) in light of contemporary chromosomal science, specifically sex chromosome aneuploidy conditions such as Turner syndrome (45X), Klinefelter syndrome (47XXY), Triple X syndrome (47XXX), and 47XYY syndrome. The study further evaluates the classical Ayurvedic classifications of hereditary disorders and their alignment with X-linked and Y-linked genetic conditions. Methods: A systematic qualitative review of classical Ayurvedic texts including Charaka Samhita (Sharirasthana), Sushruta Samhita, and Ashtanga Sangraha was conducted, with comparative analysis against peer-reviewed literature on sex chromosome abnormalities published between 2013 and 2024. Results: The Ayurvedic construct of Beejabhagavayava closely parallels the sex-determining segments of X and Y chromosomes. The clinical descriptions of Stree Vyapad (female sexual genetic disorders) map to conditions resembling Turner syndrome and Triple X phenotypes, while Purush Vyapad (male sexual genetic disorders) descriptions align with Klinefelter syndrome and 47XYY syndrome. The Ayurvedic classification of hereditary disorders into Matruja Sahaj Vikarani (maternal genetic disorders) and Pitruja Sahaj Vikarani (paternal genetic disorders) corresponds to X-linked and Y-linked inheritance patterns, respectively. Conclusion: Ayurvedic classical texts demonstrate a conceptually advanced understanding of sex determination and chromosomal-level inheritance that predates modern genetics by millennia. Integrative research bridging Ayurvedic epistemology and contemporary genomics holds promise for novel insights into sex chromosome disorders.
2026-01-31 | Prenatal Diagnosis of Sex Chromosome Aneuploidies: A Retrospective Study Using QF-PCR, SNP-Based Chromosomal Microarray Analysis, and NIPT
Objectives: This study aimed to characterize the types and frequencies of sex chromosome aneuploidies (SCAs) detected through invasive prenatal testing, evaluate the concordance between non-invasive prenatal testing (NIPT) and confirmatory diagnostic methods, and assess the challenges faced during genetic counseling following SCA diagnosis. Study Design: A retrospective review was conducted on 842 prenatal samples collected between 2020 and 2024 in a tertiary private medical center. Samples included amniotic fluid, chorionic villi, and products of conception. Testing involved rapid QF-PCR for aneuploidy detection, followed by SNP-based chromosomal microarray analysis (CMA). NIPT results with high risk for sex chromosomes aneuploidies were correlated with invasive testing outcomes in 19 cases. Results: Sex chromosome aneuploidies were identified in 67 cases (7.96%), with Turner syndrome (45, X) being the most frequent (23 cases, including six mosaics), followed by Klinefelter syndrome (18 cases), 47, XYY (14 cases), and trisomy X (12 cases). Among 19 NIPT-tested cases, 10 were true positives, 5 false positives, and 4 false negatives, including two mosaic Turner syndrome cases undetected by NIPT. Discordances were attributed to factors such as mosaicism and placental anomalies. Conclusions: Prenatal diagnosis of SCAs via invasive testing remains crucial due to NIPT's limited sensitivity for mosaicism and false positives. Comprehensive genetic counseling is essential to navigate diagnostic uncertainties and optimize prenatal management and postnatal outcomes.
2025-08-16 | Co-occurrence of Mulibrey Nanism and Jacobs Syndrome in a Pediatric Patient: Importance of Comprehensive Genetic Testing
International audience
2025-05-19 | X and Y gene dosage effects are primary contributors to human sexual dimorphism: The case of height
Many human phenotypic traits vary between the sexes, including adult height for which males are, on average, 13 cm taller than females. The biological mechanisms for this sexual dimorphism are not entirely understood. One hypothesis to explain the sexual dimorphism in height relates to differential expression in males and females of SHOX , a height-related gene in the pseudoautosomal region 1 (PAR1) on the X and Y sex chromosomes. SHOX expression is reduced on the inactive X chromosome (Xi), compared to the active X in females. Sex chromosome aneuploidies (SCAs), characterized by an atypical number of X and/or Y chromosomes, serve as informative models for investigating PAR1-related gene dosage effects. Here, we leveraged three large biobanks to study 928,605 individuals, including 1,225 adults with SCAs: 45,X (n = 95), 47,XXY (n = 505), 47,XYY (n = 290), and 47,XXX (n = 335). By modeling height across individuals with various sex chromosome complements, we quantified the contributions of five sex-related genomic contributors to height, including Xi chromosome dosage, Y chromosome dosage, male sex hormones, and effects of Klinefelter and Turner syndromes. We found that a unit increase in Y chromosome dosage confers 3.1cm (95% CI, 1.9 to 4.3) more to height than a unit increase in Xi chromosome dosage, independent of hormonal variables. The larger increase in height conferred by the Y chromosome explained 22.6% of the observed difference in height between 46,XY males and 46,XX females. This finding is consistent with the hypothesis that reduced SHOX expression in females results in a net difference in height between the sexes.
2019-06-03 | Y chromosome gene copy number and lack of autism phenotype in a male with an isodicentric Y chromosome and absent NLGN4Y expression
We describe a unique male with a dicentric Y chromosome whose phenotype was compared to that of males with 47,XYY (XYY). The male Y-chromosome aneuploidy XYY is associated with physical, behavioral/cognitive phenotypes, and autism spectrum disorders. We hypothesize that increased risk for these phenotypes is caused by increased copy number/overexpression of Y-encoded genes. Specifically, an extra copy of the neuroligin gene NLGN4Y might elevate the risk of autism in boys with XYY. We present a unique male with the karyotype 46,X,idic(Y)(q11.22), which includes duplication of the Y short arm and proximal long arm and deletion of the distal long arm, evaluated his physical, behavioral/cognitive, and neuroimaging/magnetoencephalography (MEG) phenotypes, and measured blood RNA expression of Y genes. The proband had tall stature and cognitive function within the typical range, without autism features. His blood RNA showed twofold increase in expression of Yp genes versus XY controls, and absent expression of deleted Yq genes, including NLGN4Y. The M100 latencies were similar to findings in typically developing males. In summary, the proband had overexpression of a subset of Yp genes, absent NLGN4Y expression, without ASD findings or XYY-MEG latency findings. These results are consistent with a role for NLGN4Y overexpression in the etiology of behavioral phenotypes associated with XYY. Further investigation of NLGN4Y as an ASD risk gene in XYY is warranted. The genotype and phenotype(s) of this subject may also provide insight into how Y chromosome genes contribute to normal male development and the male predominance in ASD.
small molecules
2026-04-28 | Huperzine A from Chinese Club Moss for Cognitive Enhancement via AChE Inhibition
Huperzine A, isolated from Huperzia serrata, provides highly selective acetylcholinesterase inhibition with superior CNS penetration and longer duration of action compared to conventional inhibitors. It enhances cholinergic signaling in prefrontal and hippocampal circuits while promoting neurogenesis through BDNF upregulation, addressing the learning difficulties and memory deficits in 47,XYY syndrome.
2026-04-28 | Modafinil Repurposing for Executive Function via Dopamine Transporter Modulation
Modafinil's weak dopamine transporter inhibition combined with histaminergic and orexinergic activation provides cognitive enhancement without typical stimulant side effects. Its unique mechanism addresses the executive dysfunction in 47,XYY syndrome by enhancing prefrontal dopaminergic tone while maintaining normal circadian rhythms and avoiding growth suppression concerns of traditional stimulants.
2026-04-28 | Gastrodin from Tianma (TCM) for Executive Function Enhancement via GABA-A Modulation
Gastrodin, the primary bioactive compound from Gastrodia elata, crosses the blood-brain barrier and acts as a positive allosteric modulator of GABA-A receptors while enhancing BDNF expression through CREB phosphorylation. This dual mechanism addresses the executive dysfunction and behavioral issues in 47,XYY syndrome by normalizing GABAergic inhibition and promoting neuroplasticity in prefrontal cortical circuits.
2026-04-28 | Withanoside IV from Ashwagandha for Social Cognition Enhancement via 5-HT2A Modulation
Withanoside IV, a specific withanolide from Withania somnifera, acts as a partial agonist at 5-HT2A receptors while modulating cortical glutamate release through presynaptic mechanisms. This compound addresses the social cognitive deficits in 47,XYY syndrome by enhancing prefrontal-limbic connectivity and normalizing the excitatory-inhibitory balance critical for social information processing.
2025-04-29 | An Overview of Oxidative Stress in Sex Chromosome Aneuploidies in Pediatric Populations
Background: Oxidative stress, defined as an imbalance between reactive oxygen species and antioxidant defenses, plays a pivotal role in the pathogenesis of sex chromosome aneuploidies (SCAs), such as Turner syndrome (TS) and Klinefelter syndrome (KS). Pediatric patients with SCAs are particularly susceptible due to hormonal deficiencies, metabolic disturbances, and systemic complications. Methods: A comprehensive literature search was conducted in November 2024 using PubMed, Scopus, and Web of Science. Keywords included “antioxidants”, “oxidative stress”, “pediatrics”, “Turner syndrome”, “Klinefelter syndrome”, and “sex chromosome aneuploidies”. English-language articles were included without publication year restrictions. Relevant data on oxidative stress mechanisms and antioxidant interventions were systematically extracted. Results: The relationship between oxidative stress and SCAs can be described as bidirectional, where oxidative stress both contributes to and is exacerbated by aneuploidies. TS is marked by estrogen deficiency, cardiovascular anomalies, and metabolic dysfunction, all linked to heightened oxidative stress. KS is associated with hypogonadism, metabolic syndrome, and neurocognitive challenges, further exacerbated by oxidative damage. The aneuploid condition predisposes to increased oxidative stress in other SCAs, including 47,XXX and 47,XYY, as well as in high-grade aneuploidies. Emerging evidence highlights the therapeutic potential of antioxidants, including vitamin C, vitamin E, glutathione precursors, polyphenols, and melatonin. These interventions, when combined with hormonal therapies such as estrogen replacement in TS or testosterone replacement in KS, demonstrate synergistic effects in restoring redox balance and mitigating systemic complications. Conclusions: Oxidative stress significantly impacts the progression of SCAs in pediatric populations, amplifying risks across metabolic, cardiovascular, and neurocognitive domains. Early, tailored antioxidant strategies, integrated with syndrome-specific hormonal therapies, could reduce long-term complications and improve patient outcomes. Future research should focus on standardizing protocols to optimize these interventions for pediatric patients with SCAs.
cell therapies
2022-02-02 | A patient with 47, XYY mosaic karyotype and congenital absence of bilateral vas deferens: a case report and literature review
Abstract Background The incidence of 47, XYY syndrome in live-born male infants is 1/1000. Due to its variable clinical symptoms, the diagnosis is easy to miss. The incidence of congenital bilateral absence of the vas deferens (CBAVD) in infertile men is 1–2%. The main cause is the mutation of CFTR and ADGAG2 genes. Case presentation The patient was a 33-year-old man who visited a doctor 5 years ago due to infertility. The investigation revealed that the patient’s secondary sexual characteristics, testicular, and penis development were normal, and there was no gynecomastia, but the bilateral vas deferens and epididymis were not palpable. Transrectal ultrasound showed that the left seminal vesicle was missing, and the right seminal vesicle was atrophied. No abnormality was observed in Y chromosome microdeletion. Karyotype analysis indicated that the patient was 46, XY/47, XYY mosaic. Genetic testing found heterozygous mutations at two sites of CFTR (c263T > G and c2249C > T). Conclusions Herein, we report the rare case of a male patient with clinical manifestations of infertility, chromosome 46, XY/47, XXY mosaic type, simultaneously manifested as the absence of bilateral vas deferens. Two pathogenic heterozygous CFTR gene mutations were found. Given the low genetic risk of the disease, we recommend that patients undergo intracytoplasmic sperm injection (ICSI) for fertility assessment.
2020-03-16 | Reproductive outcomes of 3 infertile males with XYY syndrome: Retrospective case series and literature review.
The aim of this study is to evaluate the pregnancy outcomes of males with a 47, XYY karyotype following assisted reproductive treatment.A retrospective study was performed using data from infertile men with 47, XYY at a center for reproductive medicine in 2004 to 2017. Of the 19,842 infertile males treated, a total of 21 showed the 47, XYY karyotype and were included in the present study. Clinical variables were collected. Three men were under treatment with their partner before either in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).The incidence of 47, XYY in infertile men is 1/945 (21/19842). Most men are azoospermic or severely oligospermic. Three men and their partners underwent IVF or ICSI treatment with fresh ejaculate samples. The fertilization rate was 52.94% to 83.33%. The embryo cleavage rate was 50% to 90%. One man had abnormal sex hormonal levels and his partner had no clinical pregnancy. The other 2 couples had healthy baby boys.Live spermatozoa can be gathered and fertility is possible for infertile males with 47, XYY syndrome when IVF or ICSI treatment is used. It is recommended that genetic counseling is provided in such cases.
2018-02-27 | Fertile offspring from sterile sex chromosome trisomic mice.
Having the correct number of chromosomes is vital for normal development and health. Sex chromosome trisomy affects 0.1% of the human population and is associated with infertility. We show that during reprogramming to induced pluripotent stem cells (iPSCs), fibroblasts from sterile trisomic XXY and XYY mice lose the extra sex chromosome through a phenomenon we term trisomy-biased chromosome loss (TCL). Resulting euploid XY iPSCs can be differentiated into the male germ cell lineage and functional sperm that can be used in intracytoplasmic sperm injection to produce chromosomally normal, fertile offspring. Sex chromosome loss is comparatively infrequent during mouse XX and XY iPSC generation. TCL also applies to other chromosomes, generating euploid iPSCs from cells of a Down syndrome mouse model. It can also create euploid iPSCs from human trisomic patient fibroblasts. The findings have relevance to overcoming infertility and other trisomic phenotypes.
2011-06-15 | Nonmosaic 47,XYY syndrome presenting with male infertility: case series
In this study, we describe nine patients with 47,XYY presenting with male infertility. All patients were subjected to history taking, clinical examination, duplex ultrasonographic examination of the scrotum, endocrinological investigations and cytogenetic analysis of peripheral lymphocytes. Two patients tried intracytoplasmic sperm injection (ICSI). Our results showed that seven patients were oligospermic and two patients were azoospermic. Bilateral varicocele was detected in seven patients. The hormonal levels in the majority of the patients were within normal range. Two patients showed improvement after varicocelectomy. The wife of one of the oligospermic patients became successfully pregnant after the first trial of ICSI. In conclusion, this report suggests that patients with XYY may present with primary infertility and may show oligospermia and nonobstructive azoospermia. Careful clinical, ultrasonographic, endocrinological and cytogenetic examinations should be a part of their diagnostic work-up for the proper management of these patients. In addition, ICSI may be a hope for some of these patients.
2005-12-01 | Intracytoplasmic sperm injection: a novel selection method for sperm with normal frequency of chromosomal aneuploidies
ObjectiveTo test a newly invented intracytoplasmic sperm injection (ICSI) sperm selection method based on sperm hyaluronic acid (HA) binding.DesignComparison of chromosomal disomy and diploidy frequencies in sperm arising from semen and in HA-bound sperm.SettingAcademic andrology laboratory.Patient(s)Men presenting for semen analysis.Intervention(s)Washed sperm fractions of 32 semen samples were applied to Petri dishes or glass slides coated with immobilized HA. The unbound sperm were rinsed gently, and the HA-bound sperm were removed with an ICSI pipette. The control sperm population was the unselected sperm. Both HA-selected and unselected sperm were treated with fluorescence in situ hybridization with centromeric probes for the X, Y, and 17 chromosomes.Main Outcome Measure(s)Chromosomal disomy and diploidy frequencies.Result(s)In the HA-bound sperm (495–2,079 per man, 41,670 in all) compared with unselected sperm (4,770 per man, 162,210 in all), the chromosomal disomy frequencies were reduced to 0.16% from 0.52%, diploidy to 0.09% from 0.51%, and sex chromosome disomy to 0.05% from 0.27% (a 5.4-fold reduction vs. 4-fold respective increase in ICSI offspring).Conclusion(s)The HA sperm selection method for ICSI, which is based on a relationship between sperm receptors for zona pellucida and HA, will likely reduce the potential genetic complications and adverse public health effects of ICSI. To test a newly invented intracytoplasmic sperm injection (ICSI) sperm selection method based on sperm hyaluronic acid (HA) binding. Comparison of chromosomal disomy and diploidy frequencies in sperm arising from semen and in HA-bound sperm. Academic andrology laboratory. Men presenting for semen analysis. Washed sperm fractions of 32 semen samples were applied to Petri dishes or glass slides coated with immobilized HA. The unbound sperm were rinsed gently, and the HA-bound sperm were removed with an ICSI pipette. The control sperm population was the unselected sperm. Both HA-selected and unselected sperm were treated with fluorescence in situ hybridization with centromeric probes for the X, Y, and 17 chromosomes. Chromosomal disomy and diploidy frequencies. In the HA-bound sperm (495–2,079 per man, 41,670 in all) compared with unselected sperm (4,770 per man, 162,210 in all), the chromosomal disomy frequencies were reduced to 0.16% from 0.52%, diploidy to 0.09% from 0.51%, and sex chromosome disomy to 0.05% from 0.27% (a 5.4-fold reduction vs. 4-fold respective increase in ICSI offspring). The HA sperm selection method for ICSI, which is based on a relationship between sperm receptors for zona pellucida and HA, will likely reduce the potential genetic complications and adverse public health effects of ICSI.
gene therapies
2026-07-07 | CRITICAL STUDY OF THE CONCEPT OF SEX CHROMOSOMES AND CHROMOSOMAL DISORDERS WITH SPECIAL REFERENCE TO STREE VYAPAD AND PURUSH VYAPAD MENTIONED IN AYURVEDA
Background: The ancient Ayurvedic texts contain sophisticated concepts regarding sex determination, hereditary disorders, and reproductive anomalies that demonstrate striking parallels with modern chromosomal science. Classical acharyas such as Charaka and Sushruta described concepts like Beeja (the biological seed — equivalent to the gamete), Beejabhaga (segments or portions of the seed analogous to chromosomes), and Beejabhagavayava (sub-segments of the chromosomal unit analogous to individual genes or sex-determining gene segments), which conceptually correlate with the modern understanding of genes, chromosomes, and sex-determining chromosomal segments. Objectives: This review critically examines the Ayurvedic concepts of Stree Vyapad (abnormal female phenotype) and Purush Vyapad (abnormal male phenotype) in light of contemporary chromosomal science, specifically sex chromosome aneuploidy conditions such as Turner syndrome (45X), Klinefelter syndrome (47XXY), Triple X syndrome (47XXX), and 47XYY syndrome. The study further evaluates the classical Ayurvedic classifications of hereditary disorders and their alignment with X-linked and Y-linked genetic conditions. Methods: A systematic qualitative review of classical Ayurvedic texts including Charaka Samhita (Sharirasthana), Sushruta Samhita, and Ashtanga Sangraha was conducted, with comparative analysis against peer-reviewed literature on sex chromosome abnormalities published between 2013 and 2024. Results: The Ayurvedic construct of Beejabhagavayava closely parallels the sex-determining segments of X and Y chromosomes. The clinical descriptions of Stree Vyapad (female sexual genetic disorders) map to conditions resembling Turner syndrome and Triple X phenotypes, while Purush Vyapad (male sexual genetic disorders) descriptions align with Klinefelter syndrome and 47XYY syndrome. The Ayurvedic classification of hereditary disorders into Matruja Sahaj Vikarani (maternal genetic disorders) and Pitruja Sahaj Vikarani (paternal genetic disorders) corresponds to X-linked and Y-linked inheritance patterns, respectively. Conclusion: Ayurvedic classical texts demonstrate a conceptually advanced understanding of sex determination and chromosomal-level inheritance that predates modern genetics by millennia. Integrative research bridging Ayurvedic epistemology and contemporary genomics holds promise for novel insights into sex chromosome disorders.
2026-01-31 | Prenatal Diagnosis of Sex Chromosome Aneuploidies: A Retrospective Study Using QF-PCR, SNP-Based Chromosomal Microarray Analysis, and NIPT
Objectives: This study aimed to characterize the types and frequencies of sex chromosome aneuploidies (SCAs) detected through invasive prenatal testing, evaluate the concordance between non-invasive prenatal testing (NIPT) and confirmatory diagnostic methods, and assess the challenges faced during genetic counseling following SCA diagnosis. Study Design: A retrospective review was conducted on 842 prenatal samples collected between 2020 and 2024 in a tertiary private medical center. Samples included amniotic fluid, chorionic villi, and products of conception. Testing involved rapid QF-PCR for aneuploidy detection, followed by SNP-based chromosomal microarray analysis (CMA). NIPT results with high risk for sex chromosomes aneuploidies were correlated with invasive testing outcomes in 19 cases. Results: Sex chromosome aneuploidies were identified in 67 cases (7.96%), with Turner syndrome (45, X) being the most frequent (23 cases, including six mosaics), followed by Klinefelter syndrome (18 cases), 47, XYY (14 cases), and trisomy X (12 cases). Among 19 NIPT-tested cases, 10 were true positives, 5 false positives, and 4 false negatives, including two mosaic Turner syndrome cases undetected by NIPT. Discordances were attributed to factors such as mosaicism and placental anomalies. Conclusions: Prenatal diagnosis of SCAs via invasive testing remains crucial due to NIPT's limited sensitivity for mosaicism and false positives. Comprehensive genetic counseling is essential to navigate diagnostic uncertainties and optimize prenatal management and postnatal outcomes.
2025-08-16 | Co-occurrence of Mulibrey Nanism and Jacobs Syndrome in a Pediatric Patient: Importance of Comprehensive Genetic Testing
International audience
2025-05-19 | X and Y gene dosage effects are primary contributors to human sexual dimorphism: The case of height
Many human phenotypic traits vary between the sexes, including adult height for which males are, on average, 13 cm taller than females. The biological mechanisms for this sexual dimorphism are not entirely understood. One hypothesis to explain the sexual dimorphism in height relates to differential expression in males and females of SHOX , a height-related gene in the pseudoautosomal region 1 (PAR1) on the X and Y sex chromosomes. SHOX expression is reduced on the inactive X chromosome (Xi), compared to the active X in females. Sex chromosome aneuploidies (SCAs), characterized by an atypical number of X and/or Y chromosomes, serve as informative models for investigating PAR1-related gene dosage effects. Here, we leveraged three large biobanks to study 928,605 individuals, including 1,225 adults with SCAs: 45,X (n = 95), 47,XXY (n = 505), 47,XYY (n = 290), and 47,XXX (n = 335). By modeling height across individuals with various sex chromosome complements, we quantified the contributions of five sex-related genomic contributors to height, including Xi chromosome dosage, Y chromosome dosage, male sex hormones, and effects of Klinefelter and Turner syndromes. We found that a unit increase in Y chromosome dosage confers 3.1cm (95% CI, 1.9 to 4.3) more to height than a unit increase in Xi chromosome dosage, independent of hormonal variables. The larger increase in height conferred by the Y chromosome explained 22.6% of the observed difference in height between 46,XY males and 46,XX females. This finding is consistent with the hypothesis that reduced SHOX expression in females results in a net difference in height between the sexes.
2019-06-03 | Y chromosome gene copy number and lack of autism phenotype in a male with an isodicentric Y chromosome and absent NLGN4Y expression
We describe a unique male with a dicentric Y chromosome whose phenotype was compared to that of males with 47,XYY (XYY). The male Y-chromosome aneuploidy XYY is associated with physical, behavioral/cognitive phenotypes, and autism spectrum disorders. We hypothesize that increased risk for these phenotypes is caused by increased copy number/overexpression of Y-encoded genes. Specifically, an extra copy of the neuroligin gene NLGN4Y might elevate the risk of autism in boys with XYY. We present a unique male with the karyotype 46,X,idic(Y)(q11.22), which includes duplication of the Y short arm and proximal long arm and deletion of the distal long arm, evaluated his physical, behavioral/cognitive, and neuroimaging/magnetoencephalography (MEG) phenotypes, and measured blood RNA expression of Y genes. The proband had tall stature and cognitive function within the typical range, without autism features. His blood RNA showed twofold increase in expression of Yp genes versus XY controls, and absent expression of deleted Yq genes, including NLGN4Y. The M100 latencies were similar to findings in typically developing males. In summary, the proband had overexpression of a subset of Yp genes, absent NLGN4Y expression, without ASD findings or XYY-MEG latency findings. These results are consistent with a role for NLGN4Y overexpression in the etiology of behavioral phenotypes associated with XYY. Further investigation of NLGN4Y as an ASD risk gene in XYY is warranted. The genotype and phenotype(s) of this subject may also provide insight into how Y chromosome genes contribute to normal male development and the male predominance in ASD.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
0 orphan drug designations.
0 orphan drug designations.
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI’s forecasts to outperform average preclinical success rates. Whether you’re expanding your R&D pipeline, evaluating a partnership, or simply have a question — we’d love to hear from you.